Combination biologic treatment of refractory psoriasis and psoriatic arthritis.
Raquel
R
Cuchacovich
Ignacio
I
Garcia-Valladares
Luis R
LR
Espinoza
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D001688:Biological Products / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008297:Male; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D016896:Treatment Outcome; D000069549:Ustekinumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D001688:Biological Products; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069549:Ustekinumab; D000068800:Etanercept